Zapping resistant tumors: could radiation keep breast cancer therapy working longer?

NCT ID NCT06925984

Recruiting now Disease control Sponsor: Jules Bordet Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether giving precise radiation (SBRT) to a few growing cancer spots can help women with ER+/HER2- metastatic breast cancer stay on their current hormone therapy or CDK4/6 inhibitor longer. The study enrolls 48 women whose cancer has started to progress in 1 to 3 places after at least 6 months on treatment. They will continue their systemic therapy while receiving SBRT to those resistant spots, with the goal of delaying the need to switch to a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: stereotactic body radiation therapy (SBRT)
What this could lead to: If successful, this approach could help women with metastatic breast cancer stay on their current well-tolerated treatment longer before needing to switch to a new one.
What could go wrong: This is a small early-phase study with only 48 participants, so results may not apply to everyone. The treatment only targets a few resistant spots, and the cancer may still progress elsewhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ER+, HER2-, METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm estrogen-receptor positive breast cancer metastatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OLIGOPROGRESSIVE METASTATIC DISEASE

Contacts and locations

Locations

AZ Groeninge
RECRUITING

Kortrijk, Belgium
AZ Sint-Maarten
RECRUITING

Mechelen, Belgium
CHU UCL Namur - Site Saint Elisabeth
RECRUITING

Namur, Belgium
Jules Bordet Institute
RECRUITING

Brussels, Belgium
UZ Gent
RECRUITING

Ghent, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.